HUE041598T2 - Újfajta citosztatikus 7-deazapurin nukleozidok - Google Patents

Újfajta citosztatikus 7-deazapurin nukleozidok

Info

Publication number
HUE041598T2
HUE041598T2 HUE16174985A HUE16174985A HUE041598T2 HU E041598 T2 HUE041598 T2 HU E041598T2 HU E16174985 A HUE16174985 A HU E16174985A HU E16174985 A HUE16174985 A HU E16174985A HU E041598 T2 HUE041598 T2 HU E041598T2
Authority
HU
Hungary
Prior art keywords
deazapurine nucleosides
new cytostatic
cytostatic
new
deazapurine
Prior art date
Application number
HUE16174985A
Other languages
English (en)
Hungarian (hu)
Inventor
Michal Hocek
Petr Naus
Original Assignee
Inst Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic filed Critical Inst Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic
Publication of HUE041598T2 publication Critical patent/HUE041598T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14Pyrrolo-pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • HELECTRICITY
    • H02GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02JELECTRIC POWER NETWORKS; CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00Circuit arrangements for charging or discharging batteries or for supplying loads from batteries
    • H02J7/40Circuit arrangements for charging or discharging batteries or for supplying loads from batteries characterised by the exchange of charge or discharge related data
    • H02J7/44Circuit arrangements for charging or discharging batteries or for supplying loads from batteries characterised by the exchange of charge or discharge related data between battery management systems and power sources
    • HELECTRICITY
    • H02GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02JELECTRIC POWER NETWORKS; CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00Circuit arrangements for charging or discharging batteries or for supplying loads from batteries
    • H02J7/485Circuit arrangements for charging or discharging batteries or for supplying loads from batteries with provisions for charging different types of batteries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Power Engineering (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
HUE16174985A 2008-01-18 2009-01-15 Újfajta citosztatikus 7-deazapurin nukleozidok HUE041598T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2224708P 2008-01-18 2008-01-18

Publications (1)

Publication Number Publication Date
HUE041598T2 true HUE041598T2 (hu) 2019-05-28

Family

ID=40434932

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE16174985A HUE041598T2 (hu) 2008-01-18 2009-01-15 Újfajta citosztatikus 7-deazapurin nukleozidok
HUE09702842A HUE030767T2 (en) 2008-01-18 2009-01-15 Novel cytostatic 7-deazapurine nucleosides

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE09702842A HUE030767T2 (en) 2008-01-18 2009-01-15 Novel cytostatic 7-deazapurine nucleosides

Country Status (18)

Country Link
US (1) US8093226B2 (enExample)
EP (2) EP2231689B1 (enExample)
JP (2) JP5485172B2 (enExample)
CN (1) CN101977923B (enExample)
AU (1) AU2009204568B2 (enExample)
CA (1) CA2711384C (enExample)
CY (2) CY1118104T1 (enExample)
DK (2) DK3133080T3 (enExample)
ES (2) ES2598503T3 (enExample)
HR (2) HRP20161344T1 (enExample)
HU (2) HUE041598T2 (enExample)
LT (2) LT2231689T (enExample)
NZ (1) NZ586610A (enExample)
PL (2) PL2231689T3 (enExample)
PT (2) PT2231689T (enExample)
SI (2) SI3133080T1 (enExample)
TR (1) TR201815961T4 (enExample)
WO (1) WO2009089804A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
HUE029236T2 (en) 2007-06-13 2017-02-28 Incyte Holdings Corp (R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
PT2421879E (pt) * 2009-04-22 2013-12-09 Acad Of Science Czech Republic Novos 7-deazapurina nucleósidos para utilizações terapêuticas
MY156727A (en) * 2009-05-22 2016-03-15 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2432472B1 (en) 2009-05-22 2019-10-02 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
AR084691A1 (es) 2010-05-21 2013-06-05 Incyte Corp Formulacion de uso topico para un inhibidor de jak y metodo para tratar trastorno de la piel
KR101817221B1 (ko) * 2010-11-18 2018-01-10 카시나 라일라 이노바 파마슈티칼스 프라이빗 리미티드 치환된 4-(셀레노펜-2(또는 3)-일아미노)피리미딘 화합물 및 이의 사용방법
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
TWI761825B (zh) 2012-11-15 2022-04-21 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
MX384910B (es) 2013-03-06 2025-03-14 Incyte Holdings Corp Procesos e intermedios para hacer un inhibidor de jak.
SG11201600815WA (en) 2013-08-07 2016-03-30 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
WO2015184305A1 (en) 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
JP6650074B2 (ja) 2016-06-29 2020-02-19 ウスタフ オルガニッケ ヘミエ アー ビオヘミエ アカデミエ ヴェド ツェーエル,ヴェー.ヴェー.イー 治療に使用するための、置換チエノピロロピリミジンリボヌクレオシド
CZ307334B6 (cs) 2016-08-02 2018-06-13 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Substituované heteropentadieno-pyrrolopyrimidinové ribonukleosidy pro terapeutické použití
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
JP7393348B2 (ja) 2018-01-30 2023-12-06 インサイト・コーポレイション (1-(3-フルオロ-2(トリフルオロメチル)イソニコチニル)ピぺリジン―4-オン)を作製するためのプロセス及び中間体
CZ308104B6 (cs) 2018-03-12 2020-01-08 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. Pyridinopyrrolopyrimidinové ribonukleosidy pro terapeutické použití
CN113768934A (zh) 2018-03-30 2021-12-10 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
WO2020206289A1 (en) * 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
BR112021025443A2 (pt) * 2019-06-18 2022-02-01 Taiho Pharmaceutical Co Ltd Compostos de éster fosfato com esqueleto de pirrolopirimidina ou sal farmaceuticamente aceitável do mesmo, agentes antitumorais e composições farmacêuticas compreendendo os ditos compostos, bem como usos e usos terapêuticos dos mesmos
WO2021164848A1 (en) * 2020-02-17 2021-08-26 Katholieke Universiteit Leuven Novel 6-substituted 7-deazapurines and corresponding nucleosides as medicaments
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN112190590A (zh) * 2020-11-06 2021-01-08 牡丹江医学院 一种治疗动脉粥样硬化的硒核苷及其药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50125033A (enExample) * 1974-03-19 1975-10-01
IL108523A0 (en) 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
JPH10158293A (ja) * 1996-08-08 1998-06-16 Rikagaku Kenkyusho 3’−デオキシリボヌクレオチド誘導体
JP3318579B2 (ja) * 1997-07-07 2002-08-26 理化学研究所 Dnaの塩基配列決定方法
JP3489991B2 (ja) * 1997-07-07 2004-01-26 理化学研究所 3’−デオキシリボヌクレオチド誘導体
CZ9901996A3 (cs) 1999-06-04 2001-01-17 Ústav organické chemie a biochemie AV ČR Nové 6-fenylpurinové 9-ß-D-ribonukleosidy s antineoplastickým účinkem, jejich použití k přípravě farmaceutických preparátů a farmaceutické přípravky, které je obsahují
AU2002353165A1 (en) * 2001-12-17 2003-06-30 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
KR20060123707A (ko) 2003-08-27 2006-12-04 바이오타, 인코포레이티드 치료제로서의 신규 트리시클릭 뉴클레오시드 또는뉴클레오티드
AU2005317081A1 (en) * 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection
CN101043893A (zh) * 2004-10-21 2007-09-26 默克公司 治疗RNA-依赖性RNA病毒感染的氟化吡咯并[2,3-d]嘧啶核苷
TW200720285A (en) * 2005-04-25 2007-06-01 Genelabs Tech Inc Nucleoside compounds for treating viral infections

Also Published As

Publication number Publication date
EP3133080B1 (en) 2018-08-01
NZ586610A (en) 2012-08-31
CA2711384C (en) 2016-07-26
CN101977923B (zh) 2014-10-08
HUE030767T2 (en) 2017-05-29
EP2231689B1 (en) 2016-07-20
US20090203637A1 (en) 2009-08-13
JP5485172B2 (ja) 2014-05-07
AU2009204568B2 (en) 2013-10-03
CA2711384A1 (en) 2009-07-23
EP2231689A1 (en) 2010-09-29
SI3133080T1 (sl) 2018-12-31
JP2014058567A (ja) 2014-04-03
EP3133080A1 (en) 2017-02-22
ES2598503T3 (es) 2017-01-27
US8093226B2 (en) 2012-01-10
DK2231689T3 (en) 2016-09-19
LT3133080T (lt) 2018-11-12
DK3133080T3 (en) 2018-11-26
HRP20181774T1 (hr) 2018-12-28
CY1118104T1 (el) 2017-06-28
TR201815961T4 (tr) 2018-11-21
CY1121364T1 (el) 2020-05-29
JP2011509949A (ja) 2011-03-31
PT2231689T (pt) 2016-10-07
CN101977923A (zh) 2011-02-16
AU2009204568A1 (en) 2009-07-23
HRP20161344T1 (hr) 2016-11-18
ES2693551T3 (es) 2018-12-12
LT2231689T (lt) 2016-10-25
PL2231689T3 (pl) 2017-01-31
PT3133080T (pt) 2018-11-16
WO2009089804A1 (en) 2009-07-23
PL3133080T3 (pl) 2018-12-31
SI2231689T1 (sl) 2016-11-30

Similar Documents

Publication Publication Date Title
PL3133080T3 (pl) Nowe cytostatyczne nukleozydy 7-deazapurynowe
BRPI0922508A2 (pt) Análogos de nucleosídeo
DK2356129T3 (da) Substituerede alpha-L-bicykliske nukleosider
BRPI0819797A2 (pt) compostos de nucleosídeos antivirais
BRPI0907435A2 (pt) Derivados de 5-flúor pirimidina
BRPI0813707A2 (pt) Derivados de pirimidinil-piridazinona
BRPI0820112A2 (pt) Derivados de isoxazol-piridina
BRPI0809992A2 (pt) Derivados de pirrolopirimidina
BRPI0820113A2 (pt) Derivados de isoxazolo-piridazina
DK2308877T3 (da) Imidazopyridin-2-on-derivater
BRPI0916233A2 (pt) compostos heterocíclicos antivirais
BRPI0812155A2 (pt) derivados de espiroindolinona
BRPI0817935A2 (pt) Derivados de biarila
BRPI0915064A2 (pt) derivados de qunoxalinadiona
DK2511282T3 (da) Uracylspirooxetannukleosider
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI0814236A2 (pt) Derivados de quinazolinamida
BRPI0812518A2 (pt) Derivados de indazolamida
BRPI0820649A2 (pt) Derivados de isoxazalo-pirazina
BRPI0910534A2 (pt) terapia antiviral
DK2275414T3 (da) Cyclopentylacrylamidderivat
BRPI0920496A2 (pt) derivados substituídos de pirimidina etriazina
BRPI0924121A2 (pt) compostos antivirais heterocíclicos
ATE545635T1 (de) Substituierte n-oxidpyrazinderivate
BRPI0922652A2 (pt) Derivados de quinazolinamida